The U.S. Food and Drug Administration (FDA) released a draft guidance designed to accelerate the approval and market entry of biosimilar drugs — lower-cost alternatives to expensive biologic medicines. The initiative seeks to simplify bioequivalence studies and reduce unnecessary clinical testing, according to an official FDA statement.
Biologic therapies accounted for just 5% of total prescriptions in 2024, yet represented 51% of overall drug spending, the agency noted. These advanced medicines are widely used to treat cancer, autoimmune disorders, and rare diseases, making access and affordability critical concerns.
Reducing Barriers to Affordable Treatments
So far, the FDA has approved 76 biosimilar therapies, but only ten percent of brand biologics expected to lose patent protection over the next decade currently have a biosimilar in development. The new draft guidance aims to close this gap by removing redundant requirements and making biosimilar development more efficient and cost-effective.
Government Push to Lower Drug Prices
“Today’s announcement of biosimilar reform furthers President Trump’s directive to lower drug prices for the American people,” said HHS Secretary Robert F. Kennedy Jr. “Biologics treat many chronic diseases, but for too long, a burdensome approval process has kept patients from accessing more affordable biosimilars,” informed Kennedy Jr.
Reducing Costs and Development Timelines
Under the current framework, biosimilar approvals typically take one to three years and cost developers an average of $24 million. These processes often require extensive comparative efficacy studies to demonstrate similarity with reference biologics.
The new FDA guidance, however, reduces these resource-intensive requirements, allowing developers to rely more on analytical and structural testing rather than human clinical studies. “This will enable faster development without compromising safety or efficacy standards,” the agency emphasized.
Accelerating Access to Life-Saving Therapies
By cutting approval timelines and costs, the FDA hopes to stimulate biosimilar innovation and expand patient access to affordable treatments. As reported by msn.com, the move aligns with broader U.S. health policy efforts to reduce drug prices and strengthen competition in the biologics market — ultimately helping patients receive effective therapies at lower costs.
